Crispr Therapeutics (NASDAQ:CRSP) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, January 1st, BidAskClub reports.
Other equities research analysts also recently issued research reports about the stock. TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Oppenheimer upped their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $75.95.
Shares of Crispr Therapeutics stock traded down $1.82 on Wednesday, hitting $54.75. The company had a trading volume of 1,224,856 shares, compared to its average volume of 1,021,665. The business has a 50-day simple moving average of $63.18 and a 200-day simple moving average of $52.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company has a market cap of $3.12 billion, a PE ratio of -119.02 and a beta of 3.20. Crispr Therapeutics has a 52 week low of $29.34 and a 52 week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, equities research analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $465,000. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 over the last quarter. 21.40% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA acquired a new stake in Crispr Therapeutics during the second quarter worth about $41,000. Aperio Group LLC acquired a new stake in Crispr Therapeutics during the second quarter worth about $153,000. Swiss National Bank grew its stake in Crispr Therapeutics by 28.6% during the second quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after buying an additional 10,800 shares in the last quarter. Wells Fargo & Company MN grew its stake in Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in Crispr Therapeutics during the second quarter worth about $466,000. Hedge funds and other institutional investors own 49.83% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.